| Mary Roberts, | |
|
2807 Greystone Commercial Blvd Ste 36, Birmingham, AL 35242-9601 | |
| (205) 552-0417 | |
| (205) 408-3441 |
| Full Name | Mary Roberts |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 2807 Greystone Commercial Blvd Ste 36, Birmingham, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073060471 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 4473C (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mary Roberts, 5101 Cyrus Cir, Birmingham, AL 35242-4631 Ph: (205) 453-7878 | Mary Roberts, 2807 Greystone Commercial Blvd Ste 36, Birmingham, AL 35242-9601 Ph: (205) 552-0417 |
News Archive
Genovate Biotechnology Co. Ltd. and ScinoPharm Taiwan Ltd. announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B. It is expected to be commercially available by the end of the year in Taiwan, accounting for more than NT$2 billion (US$70 million) worth of market opportunity.
A new article published in the Cell Reports describes how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome in preclinical models.
HGPS is a rare genetic disease that affects one in every 4-8 million births. The disease is caused by a spontaneous mutation in one of the two copies (alleles) of the gene LMNA, which codes for lamin A, a protein important for the integrity and function of the envelope surrounding the cell nucleus. The mutation causes incorrect processing of the messenger RNA for lamin proteins, resulting in the synthesis of an anomalous protein, called progerin.
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
› Verified 7 days ago
Tara L Foley, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3600 7th Ct S Ste 100, Birmingham, AL 35222 Phone: 205-945-7483 Fax: 205-945-7083 | |
Page Rubin, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 300 Century Park S Bldg 300, Birmingham, AL 35226 Phone: 205-942-3200 | |
Christa Devaughn Brown, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3220 5th Ave S Ste 100, Birmingham, AL 35222 Phone: 205-877-8677 Fax: 205-877-8675 | |
Amy Daniel Pribyl, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Muriel C. Thompson, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1037 22nd Street South, Suite 200, Birmingham, AL 35205 Phone: 205-326-1513 Fax: 205-326-1514 | |
Mrs. Dorinda A Smith, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 129 E Park Cir, Birmingham, AL 35235 Phone: 205-836-7283 Fax: 205-836-9594 | |
Melissa Evans, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 700 19th St S, Birmingham, AL 35233 Phone: 205-369-0865 |